IFG Advisory
CRSP icon

IFG Advisory’s CRISPR Therapeutics CRSP Stock Holding History

IFG Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$36.6K Hold
661
– – ﹤0.01% 1420
2026
Q2 		$36.1K Buy
+661
New +$34.8K ﹤0.01% 1441
2021
Q3 		– Sell
-7,223
Closed -$1.17M – 483
2021
Q2 		$1.17M Buy
+7,223
New +$878K 0.13% 183

Other funds holding CRSP

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

IFG Advisory's CRSP Position: Q3 2026 in Review

IFG Advisory held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 661 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1420.

IFG Advisory first reported a position in CRSP in Q2 2021 and has held it in 3 quarters since. The position peaked at $1.17M in Q2 2021. 257 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • IFG Advisory held 661 shares of CRISPR Therapeutics worth $36.6K as of Q3 2026.
  • IFG Advisory left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of IFG Advisory's portfolio in Q3 2026, its #1420 holding.
  • IFG Advisory first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • IFG Advisory's CRISPR Therapeutics position peaked at $1.17M in Q2 2021.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on IFG Advisory's 13F filing for Q3 2026, filed 9 Nov 2026.